AstraZeneca Prilosec Patent Trial Hinges On Definition Of “Subcoating”
Executive Summary
The outcome of AstraZeneca's Prilosec patent case will likely hinge on the Manhattan federal court's interpretation of the term "subcoating.
You may also be interested in...
Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz
Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not
Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz
Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not
Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity
Schwarz Pharma is exploring a scenario where it would win a favorable decision in the Prilosec patent case, while generic omeprazole marketing exclusivity holder Andrx loses on non-infringement